Dewpoint, Novo Nordisk to identify drug candidates for diabetic complications
Dewpoint’s discovery platform related to biomolecular condensates will be used to identify the drug candidates. The collaboration will enable combination of Novo Nordisk’s expertise in treating diabetes and